News and Events TinexylPRO Launched at Key Industry Events May 27, 2024 Appointment of Dr Trevor Phillips to the Board of NovaBiotics Sep 6, 2023 Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms Aug 16, 2023 Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics Jan 23, 2023 NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases Apr 21, 2022 NovaBiotics to Present at the H.C. Wainwright BioConnect Conference Jan 4, 2022 NovaBiotics Announces First Patient Enrolment into the Cysteamine Domain of REMAP-CAP Dec 8, 2021 NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference Nov 1, 2021 NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology Oct 5, 2021 NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF) Sep 23, 2021 « Older Entries Categories Press Releases Events In the news Archives 2021 2020 2019
Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms Aug 16, 2023
Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics Jan 23, 2023
NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases Apr 21, 2022
NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology Oct 5, 2021
NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF) Sep 23, 2021
